News

View
New AMD drug completes Phase 2 trial
EyePoint

New AMD drug completes Phase 2 trial

EyePoint Pharmaceuticals announced the completion of the Phase 2 trial of their new experimental drug, vorolanib, for the treatment of wet age-related macular degeneration.
New eye drops may be potential new treatment for wet AMD
intravitreal injection

New eye drops may be potential new treatment for wet AMD

The current available therapies available to treat wet AMD involve intravitreal injections delivered every month to the back of the eye. 
Regeneron receives FDA approval for EYLEA HD
diabetic macular edema

Regeneron receives FDA approval for EYLEA HD

The Food and Drug Administraton (FDA) gave approval after two active-controlled, double-masked pivotal trials, which compared EYLEA HD to EYLEA over a 48 week period.
FDA approves Izervay for treatment of geographic atrophy
AMD

FDA approves Izervay for treatment of geographic atrophy

The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.

USA Only, Spend $50, get free shipping

Free shipping is currently available for orders within the United States only.